Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipramine in fascin1-overexpressing colorectal and triple-negative breast cancer
2021-001328-17Phase 2Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) comparing Imipramine with Placebo (2 arms). Primary endpoint: Histological traits of the invasive tumor front. Started Sep 2021; status: active.
02
Drugs
imipramine
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2021-001328-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001328-17.